Skip to main content
Lotus Endometriosis Institute solid color logo
A beautiful landscape of lotus flowers

Can Hormone Treatment Calm Adenomyosis Symptoms Over Time? What an 18 Month Follow Up Study Found

An evidence-based look at 18‑month outcomes of hormone therapy for adenomyosis—symptom relief, ultrasound changes, side effects, and what it means for you.

By Dr Steven Vasilev
A woman sits at a sunlit kitchen table reviewing an 18‑month hormone therapy timeline on a tablet, with a pill organizer and clipped ultrasound printouts beside her.

Living with adenomyosis can mean planning your life around pain and bleeding—painful periods (dysmenorrhea), heavy menstrual bleeding, and sometimes other ongoing pelvic pain symptoms that don’t neatly follow a calendar. If you also have endometriosis, the picture can feel even more complicated, because symptoms may overlap and imaging findings can change over time.


A 2025 study in the Journal of Personalized Medicine followed premenopausal people with ultrasound evidence of adenomyosis (with and without endometriosis) for 18 months to see what happened to symptoms and ultrasound findings in those who used continuous hormonal treatment compared with those who did not. This kind of real‑world, longer follow‑up matters because many patients are trying to decide whether staying on medication is “worth it” over time—especially when side effects are part of the trade‑off.


This article walks through what the study observed, what it might mean for day‑to‑day decision-making, and what the study cannot prove.


Key Findings


Why this study was done


The researchers aimed “to evaluate the impact of hormonal therapy” on painful symptoms over “an 18‑month follow‑up,” and they also wanted to “explore sonographic changes” (changes seen on ultrasound) alongside symptoms. In other words, they weren’t only asking, “Do people feel better?”—they also asked, “Does the uterus (and any coexisting endometriosis) look different on imaging over time?”


Importantly, this was described as a pilot retrospective observational study. That means the researchers looked back at what happened in a group of patients rather than randomly assigning treatment.


Who was included (and how adenomyosis/endometriosis were assessed)


The study included “40 women with ultrasound evidence of adenomyosis with and without endometriosis.” Symptoms were tracked using a VAS (Visual Analog Scale), described as a “10 cm Visual Analog Scale,” where 0 means no pain and 10 means the maximum pain.


Adenomyosis and endometriosis were assessed by ultrasound during follow‑up. The paper also notes that there is “no consensus currently exists within the MUSA group” for grading severity in a standardized way, which matters when interpreting how “mild” vs “severe” disease is classified across studies.


What treatment was studied


Twenty patients initiated treatment: “Twenty patients initiated continuous progestin therapy with Dienogest 2 mg per day.” The comparison group was not a placebo group; it consisted of people who chose not to use hormonal treatment: “twenty declined hormonal treatment.” That choice is important, because people who accept or decline treatment can differ in ways that affect outcomes (for example, symptom severity, side-effect concerns, or other health factors), even if those differences aren’t fully captured in the data.


Symptom changes over time


One of the most striking reported findings was for dysmenorrhea and heavy menstrual bleeding in the treated group. The authors report that these symptoms “completely disappear in patients on continuous hormone therapy,” with dysmenorrhea changing from “VAS 7 ± 1.8 SD T0 vs. VAS 0 after 6 months,” and this improvement was sustained through 18 months per the study’s summary claim.


In contrast, among people who did not receive hormonal therapy, the paper reports that “symptoms either remain unchanged or may worsen over time.” Because this was not a randomized trial, the study cannot prove treatment caused the differences—but it does describe two clearly different symptom trajectories in the groups they followed.


The paper also notes that not every symptom improved to zero for everyone. It reports that other pain symptoms improved more slowly and did not always fully resolve, with “VAS scores decreasing to 4 after 18 months” for those symptoms (the study does not provide further detail in the extracted summary about which specific symptoms were included in this “other pain” category).


Ultrasound changes: what happened to adenomyosis and endometriosis findings?


The study also tracked what the disease looked like on ultrasound over time.


In the treated group, the authors describe a “progressive reduction in focal adenomyosis among treated patients,” with focal adenomyosis reported as “25%… 15%… 10% at 18 months.” In the untreated group, ultrasound suggested “worsening in disease extent,” including a shift toward more diffuse or mixed patterns.


For participants with endometriosis, there was a specific finding about endometriomas (ovarian cysts related to endometriosis). In treated patients with endometriomas, the maximum diameter decreased significantly by 18 months, from “T0: 38.4 ± 11.1 mm vs. T3: 18.5 ± 8.1 mm.” The study summary also states that “other endometriosis sites were stable in size.” The extracted analysis notes that the number of treated patients with concomitant endometriosis was not fully detailed in the Results and appears to rely on a table reference.


Ready to Take Control of Adenomyosis?

Our specialists are here to help you understand your condition and explore your treatment options.

Schedule Your Visit

Side effects reported with treatment


Symptom relief is only one side of the equation. This study reported a notable rate of side effects in the hormone-treated group: by 18 months, “nearly half of the patients undergoing hormone therapy experienced hypoestrogenism-related side effects.” The examples listed include “vaginal dryness, decreased libido, and mood disturbances.” The study reports that none of these symptoms were reported in the untreated group (“no patients in the non-treatment group”).


Hypoestrogenism-related side effects are symptoms that can happen when estrogen effects in the body are reduced. The study does not report strategies for preventing or treating these side effects, and it does not report whether side effects led anyone to stop treatment.


What This Means For You


If you are deciding whether to try (or stay on) continuous dienogest for adenomyosis symptoms, this study offers a real-world picture of what may happen over a longer stretch of time—while also showing the trade‑offs.


Here are the most practical takeaways that come directly from what the researchers reported:

    • In this study, people who took continuous dienogest (2 mg/day) had dysmenorrhea and heavy menstrual bleeding drop to zero by 6 months and stay improved through 18 months (“VAS 0 after 6 months”).
    • If you choose not to use hormonal treatment, this study observed that symptoms “either remain unchanged or may worsen over time” during 18 months of follow‑up.
    • Imaging did not stay static: ultrasound findings appeared more stable or improving with treatment and more worsening without treatment, including “worsening in disease extent” in untreated patients. If you’re already getting ultrasounds, you may want to ask your clinician whether regular follow‑up imaging could help track changes over time in your specific case.
    • Side effects are not rare. By 18 months, “nearly half” of treated patients reported hypoestrogenism-related issues such as “vaginal dryness, decreased libido, and mood disturbances.” If you start treatment, consider planning ahead with your clinician for side‑effect monitoring and what you’ll do if they become disruptive.

This study does not report fertility outcomes, pregnancy outcomes, or whether treatment changed the need for surgery—so if those are your main concerns, you’ll need other evidence and individualized counseling.


Important Limitations


This study provides useful clues, but there are several reasons to treat the findings as suggestive rather than definitive:

    • It cannot prove cause and effect. This was a “pilot retrospective observational study,” meaning people were not randomized to treatment. Improvements could be associated with treatment without being solely caused by it.
    • The sample was small. Only “40 patients” were included, which limits how confidently these results apply to the broader adenomyosis/endometriosis community.
    • Ultrasound grading is not fully standardized. The authors state “no consensus currently exists within the MUSA group” for severity grading, so “improvement” or “worsening” on ultrasound may not translate perfectly across different clinics or studies.
    • Some outcomes are suggested, not demonstrated. The paper discusses future possibilities (including fertility-related questions), but this study itself does not demonstrate fertility preservation or improved reproductive outcomes; the abstract notes “Further larger-scale... studies are needed.”

References

  1. Martire Francesco Giuseppe; d’Abate Claudia; Costantini Eugenia; De Bonis Maria; Sorrenti Giuseppe; Centini Gabriele; Zupi Errico; Lazzeri Lucia. “Sonographic and Clinical Progression of Adenomyosis and Coexisting Endometriosis: Long-Term Insights and Management Perspectives …” Journal of Personalized Medicine. 2025. DOI: not reported in this study. DOI: 10.3390/jpm15110538

Quick Answers

When is menstrual bleeding considered too heavy?

Menstrual flow is generally “too heavy” when it consistently disrupts your life or overwhelms your usual period products—think flooding or soaking through pads/tampons quickly, passing frequent or large clots, needing to double up, or bleeding long enough that you can’t plan around it. Another major clue is fatigue, dizziness, or shortness of breath that can come with iron deficiency from ongoing blood loss. If you’re timing your day around bathrooms, waking at night to change products, or avoiding work, exercise, travel, or sex because of bleeding, that’s not something we consider “normal.”


Heavy bleeding is a symptom, not a diagnosis, and common underlying drivers include adenomyosis, fibroids, hormonal imbalance, and sometimes endometriosis—especially when heavy bleeding shows up with severe cramps or deep pelvic pain. Because imaging and symptoms don’t always match (a scan can look “mild” while symptoms are intense), we take a symptom-led approach and look at the full pattern, including pain, pressure, clots, cycle timing, and any signs of anemia. If your bleeding feels like it’s escalating or you’ve been told to “just live with it,” our team can help you sort out likely causes and build a plan that targets the source—not just the bleeding.

Read full answer

Can endometriosis cause arthritis-like joint pain?

Yes—endometriosis can be associated with arthritis-like joint pain in some people, even though joint pain isn’t considered a classic “core” symptom. Endometriosis can drive chronic inflammation and immune dysregulation, and that whole-body inflammatory state may show up as aching, stiffness, or flares that feel similar to inflammatory arthritis. Some patients also notice joint symptoms that cycle with their period or worsen during broader endometriosis flares.


At the same time, endometriosis doesn’t “equal” autoimmune arthritis, and an association doesn’t prove that one causes the other. Research suggests higher rates of certain autoimmune conditions in people with endometriosis—including inflammatory diseases that can affect joints—so persistent joint pain deserves a full-picture evaluation rather than being automatically attributed to pelvic disease alone. If you’re dealing with pelvic pain plus joint symptoms, our team can help you sort out what fits endometriosis, what may be a related immune condition, and how that affects your treatment plan, including whether excision surgery and coordinated integrative support make sense for you.

Read full answer

How does estrogen affect the endometrium?

Estrogen is one of the main hormones that drives endometrial growth. In the first half of the menstrual cycle, rising estrogen signals the endometrium to thicken and rebuild after a period, preparing the uterus for a possible pregnancy. It also influences the local immune and inflammatory environment in the uterus, which is part of why hormonal shifts can change bleeding patterns and pain.


When estrogen’s growth signals are strong—and progesterone’s “calming” effect is weaker than expected (often described as progesterone resistance)—the endometrium can behave in a more persistently inflamed, reactive way. This hormone–inflammation pattern is especially relevant in estrogen-dependent conditions like adenomyosis and endometriosis, where tissue similar to the endometrium can contribute to ongoing symptoms. If you’re trying to make sense of heavy bleeding, severe cramping, or cycle-linked pelvic pain, our team can help you connect the hormonal biology to what you’re feeling and review next steps for diagnosis and treatment.

Read full answer

What does advanced adenomyosis mean?

“Advanced adenomyosis” usually means the adenomyosis is more extensive within the uterine muscle—often involving a larger area (diffuse disease), deeper penetration into the myometrium, and/or more pronounced changes like uterine enlargement and tenderness. It’s not the same as “advanced endometriosis,” because adenomyosis doesn’t spread outside the uterus; “advanced” is more about how much of the uterine wall appears affected and how significantly it’s impacting symptoms.


Because adenomyosis doesn’t have a single universally accepted staging system, different clinicians and radiology reports may use “advanced” to summarize imaging features (ultrasound or MRI) and the overall clinical picture—such as heavy bleeding, severe period pain, pelvic pressure, or fertility challenges. In our practice, we focus less on the label and more on what your imaging suggests (diffuse vs focal/adenomyoma, junctional zone changes, uterine size) and what your goals are (pain control, bleeding control, fertility preservation, or definitive treatment). If you’ve been told you have “advanced adenomyosis,” our team can help you interpret what that means in your specific case and map out next steps.

Read full answer

How long do endometriosis flare-ups last?

Endometriosis flare-ups don’t have one “usual” length—some people feel a spike in symptoms for a few hours to a couple of days, while others have flares that stretch across an entire cycle window or blend into more constant pain. Many flares track with hormonal shifts (often before and during a period), but bowel, bladder, pelvic floor, or nerve-related pain can flare at different times and may not follow a neat calendar pattern.


When flares start lasting longer or happening more often, it can be a sign that multiple pain drivers are stacking—ongoing inflammation from lesions, adhesions/fibrosis that can “tether” organs, and sometimes central sensitization, where the nervous system becomes more reactive over time. That’s why symptom management alone can feel like a band-aid if active disease is still present. If you’re noticing prolonged, unpredictable, or escalating flares, our team can help you map your pattern, identify what’s likely driving it, and discuss a plan that addresses both symptom control and the underlying endometriosis.

Read full answer

Reach Out

Have a question?

Dr. Steven Vasilev delivers best-in-class endometriosis guidance and a personalized treatment plan—built on evidence and your unique biology.


Led by Steven Vasilev, MD—an internationally recognized endometriosis specialist & MIGS surgeon—Lotus Endometriosis Institute is virtual-forward, with many patients traveling nationally for care. Clinical evaluation and surgical treatment are provided in California.

Santa Monica, CA

2121 Santa Monica Blvd, Santa Monica, CA 90404

Operating Hours

8:00 am - 5:00 pm
Monday - Friday

Arroyo Grande, CA

154 Traffic Way, Arroyo Grande, CA 93420